Company Filing History:
Years Active: 2014
Title: Jörn Stitz: Innovator in Retroviral Vector Technology
Introduction
Jörn Stitz is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of retroviral vector particles. His work focuses on enhancing methods for host cell transduction, which has implications for therapeutic applications.
Latest Patents
Jörn Stitz holds a patent for "Retroviral vector particles and methods for their generation and use." This invention relates to methods of host cell transduction utilizing ecotropic retroviral vector particles. The retroviral vector particle may comprise an envelope of Friend murine leukaemia virus, specifically the envelope encoded by molecular clone PVC-211. The host cell may be engineered to recombinantly express the Reel receptor. The retroviral vector particles and methods of this invention can introduce expressible polynucleotide sequences of interest into host cells with high efficiency. This results in protein production methods with higher yield (mg/L) and a reduction in manufacturing costs, which could be utilized in various applications, including the production of therapeutic proteins, vaccines, and antibodies.
Career Highlights
Throughout his career, Jörn Stitz has worked with several prominent companies in the biotechnology sector. Notable among these are 4-Antibody AG and Agenus Inc. His experience in these organizations has contributed to his expertise in the field and has facilitated his innovative work.
Collaborations
Jörn Stitz has collaborated with various professionals in his field, including Ulf Grawunder. These collaborations have likely enhanced his research and development efforts, leading to advancements in retroviral vector technology.
Conclusion
Jörn Stitz is a distinguished inventor whose work in retroviral vector technology has the potential to revolutionize therapeutic protein production. His innovative approaches and collaborations continue to influence the biotechnology landscape.